RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 New MS Drugs
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 2
SP 10
OP 12
DO 10.1177/155989771202008
UL http://mdc.sagepub.com/content/12/2/10.abstract
AB Multiple sclerosis (MS) affects more than 350,000 people in the United States (US) and 2.5 million people worldwide. In the US alone, the health care costs that are associated with the treatment of MS are estimated to be more than $10 billion annually. Recently approved or investigational agents in advanced development have the potential to significantly improve outcomes for patients with relapsing-remitting MS [Fox EJ, Rhoades RW. Curr Opin Neurol 2012].